MetaCap

Royalty Pharma plc Class A (RPRX)

NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

68.45+0.73 (+1.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RPRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$39.36B
Dividend yield
1.35% ($0.925)
Ex-dividend date
Nov 13, 2026
52-week range
37.31 – 70.37
Day range
67.95 – 68.83
Volume / Avg
3.53M / 3.21M
Beta
—

52-week range

$37.31$70.37

RPRX stock today

On Nov 20, RPRX ended the session at $68.45, adding $0.73 (1.08%), versus the S&P 500's 3.70% decline. At this level, RPRX sits near the top of its 52-week range of $37.31 to $70.37: 2.7% below the high, set on Nov 12, 2026 and 83.5% above the low. RPRX is up 77.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 75.9%.

At 44.7x trailing earnings, Royalty Pharma trades in line with the peer-group median of 43.2x. Its forward P/E of 11.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Royalty Pharma pays an annual dividend of $0.925 per share, a 1.35% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Royalty Pharma

Company profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Pablo Legorreta
Headquarters
New York, NY
Employees
100
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Royalty Pharma generated $2.38 billion in revenue, up 5.1% from fiscal 2024. Net income was $770.9 million (-10.2% year over year), for a net margin of 32.4% versus a median of 37.9% in the prior 5 years. Operating margin was 65.6%.

Royalty Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B
Growth+5.06%-3.86%+5.24%-2.28%+7.87%
Net income$770.95M$858.98M$1.13B$42.83M$619.73M
EPS (diluted)$1.78$1.91$2.53$0.10$1.49

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$75.25+9.93%

  • Strong buy 2
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $67.00High $80.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.32 vs $1.18
Surprise
-72.88%

Dividends

Dividend history
Annual dividend
$0.925
Last payment
$0.235
Ex-dividend date
Nov 13, 2026
Pay date
Dec 10, 2026

RPRX news

All RPRX news

Royalty Pharma peers

Health Care sector
RPRX peer companies
CompanyPrice% ChgMarket capCompare
ONCBeOne Medicines Ltd. ADR390.94-2.19%$44.66Bvs RPRX
ZTSZoetis Inc. Class A79.11-2.08%$32.14Bvs RPRX
TEVATeva Pharmaceutical Industries Limited39.23+1.79%$45.77Bvs RPRX
GMABGenmab A/S ADS50.60-1.46%$31.20Bvs RPRX
INSMInsmed Incorporated141.33-2.17%$31.01Bvs RPRX
ROIVRoivant Sciences Ltd.38.66-0.78%$28.01Bvs RPRX
UTHRUnited Therapeutics Corporation554.73-0.78%$23.63Bvs RPRX
VTRSViatris Inc.19.63-1.26%$22.50Bvs RPRX

Indexes, lists and sector

Royalty Pharma stock FAQ

What is Royalty Pharma's stock price today?

RPRX last traded at $68.45 as of Nov 20, 4:00 PM EST, up 1.08% on the day. Prices are delayed at least 15 minutes.

Does Royalty Pharma pay a dividend?

Yes. Royalty Pharma pays $0.925 per share annually, a 1.35% yield. The most recent dividend of $0.235 had an ex-dividend date of Nov 13, 2026.

What is RPRX's P/E ratio?

RPRX trades at a trailing P/E ratio of 44.74 and a forward P/E of 11.62, compared with a median of 43.2 for its closest peers.

Who is Royalty Pharma's CEO?

Mr. Pablo Legorreta is the chief executive officer of Royalty Pharma plc Class A, which has about 100 employees.

What is the RPRX 52-week high?

The 52-week high for RPRX is $70.37 and the 52-week low is $37.31. The stock is currently 2.7% below its high.

Compare RPRX